Skip to main content

AN OPEN LABEL PHASE Ia/b DOSE ESCALATION FOLLOWED BY DOSE EXPANSION SAFETY AND TOLERABILITY TRIAL OF CAP 100, A HUMANIZED C C CHEMOKINE RECEPTOR 7 ANTIBODY, ADMINISTERED AS MONOTHERAPY IN SUBJECTS WITH R/R CHRONIC LYMPHOCYTIC LEUKEMIA

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Catapult Therapeutics BV

Start Date

August 9, 2021

End Date

September 5, 2026
 

Administered By

Duke Cancer Institute

Awarded By

Catapult Therapeutics BV

Start Date

August 9, 2021

End Date

September 5, 2026